Studies to be presented at the forthcoming American Society of Clinical Oncology meeting in Orlando, Florida, at the end of the month, show that German drugmaker Merck Serono's leading oncology product Erbitux (cetuximab), when added to standard chemotherapy or radiotherapy regimens, significantly improves treatment efficacy in metastatic colorectal cancer, squamous cell carcinoma of the head and neck and non-small cell lung cancer, without significantly affecting overall quality of life.
Other study findings at ASCO will highlight Erbitux' potential in a number of new cancer types, such as gastric and biliary, in combination with a range of different standard chemotherapy and radiotherapy regimens.
Erbitux in combination with irinotecan/5-fluorouracil/folinic acid for the first-line treatment of advanced gastric cancer was well tolerated with encouraging survival data. This novel combination regimen yielded an overall tumor response rate of 42%, with median progression-free survival and overall survival times of 8.5 and 16.6 months, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze